Recurrent BV: Labs, Root Causes, and Next Steps for Women Who Keep Getting It Back

Why BV Comes Back: The Root-Cause Picture

Recurrent bacterial vaginosis is not a treatment failure in the simple sense. You may have taken every metronidazole pill correctly and still watched symptoms return within weeks. The reason is that standard antibiotics suppress the overgrowth of anaerobic organisms like Gardnerella vaginalis and Prevotella species, but they rarely restore the protective Lactobacillus-dominant microbiome that keeps pH low and BV organisms at bay.

Studies using 16S rRNA sequencing show that women with recurrent BV tend to harbor a polymicrobial biofilm on the vaginal epithelium. That biofilm, primarily composed of Gardnerella vaginalis, protects anaerobes from antibiotic penetration and seeds re-infection after treatment ends.

The Vaginal Microbiome Is the Central Issue

A healthy vaginal microbiome in reproductive-age women is dominated by Lactobacillus crispatus or Lactobacillus iners. L. Crispatus produces lactic acid and hydrogen peroxide, keeping vaginal pH below 4.5. When this community collapses, opportunistic anaerobes fill the gap.

A landmark 2019 cohort published in Nature Medicine followed 135 women and found that those colonized primarily with L. Iners rather than L. Crispatus were significantly more likely to transition to a BV-associated community. L. Iners is the less stable of the two species and does not produce hydrogen peroxide.

Hormonal Drivers at Every Life Stage

Estrogen directly stimulates vaginal epithelial cells to produce glycogen, which Lactobacillus species ferment into lactic acid. When estrogen drops, the fuel supply for Lactobacillus shrinks.

Reproductive years. Estrogen peaks mid-cycle, so the mid-luteal phase is typically the most protected window. Menstruation raises vaginal pH transiently above 4.5 every month, creating a window for anaerobic regrowth. Research published in PLOS ONE confirmed that pH rises above 4.7 during menses even in women who do not have BV.

Perimenopause. As ovarian estrogen production becomes erratic and then declines, the vaginal epithelium thins and Lactobacillus colonization decreases. Women in late perimenopause and early postmenopause experience a vaginal microbiome shift that overlaps mechanistically with recurrent BV, even without a sexual exposure trigger. The Menopause Society notes that genitourinary syndrome of menopause (GSM) and recurrent vaginal infections share a common root in estrogen withdrawal.

Postpartum. Estrogen drops sharply after delivery and stays low during lactation, particularly with exclusive breastfeeding. Postpartum women are therefore at elevated biological risk for microbiome disruption.

PCOS. Women with polycystic ovary syndrome often have androgen excess, irregular cycles, and altered cervicovaginal immune responses. A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that androgen excess is associated with altered vaginal microbiome composition, though the direction of causality is not fully established.

Sexual Behavior and Transmission Factors

BV is not classified as a sexually transmitted infection, but sexual activity is the strongest behavioral risk factor for recurrence. Semen has a pH of approximately 7.2 to 8.0, which temporarily alkalinizes the vaginal environment after unprotected intercourse. ACOG Practice Bulletin 215 acknowledges that new or multiple sexual partners increase BV risk.

Women who have sex with women have higher BV prevalence and concordance between partners, supporting a degree of sexual transmission even absent a male partner.

Symptoms That Signal Recurrence (and When to Act Fast)

Recurrent BV symptoms are often subtler on repeat episodes than the first time, or they may be absent entirely. Recognizing the pattern matters.

Classic Symptom Cluster

• Thin, gray or off-white vaginal discharge
• A "fishy" or amine odor, often stronger after intercourse or during menses
• Mild vaginal irritation or burning, though itching is less characteristic than with yeast
• Vaginal pH above 4.5 on self-test strips (available over the counter)

Importantly, up to 50 percent of women with laboratory-confirmed BV report no symptoms at all, according to CDC treatment guidelines for vaginal infections. This is one reason self-diagnosis using symptoms alone leads to mistreatment.

Symptoms That Warrant Same-Week Evaluation

Seek care promptly if you have any of these alongside BV symptoms:

• Fever above 38.0°C or pelvic pain (raises concern for pelvic inflammatory disease)
• Purulent or bloody discharge not explained by menses
• Symptoms during pregnancy at any gestational age
• BV recurrence within four weeks of completing antibiotics

Labs and Diagnostic Testing for Recurrent BV

A single positive whiff test and clue cells on microscopy are sufficient to diagnose a first episode. For recurrent BV, the diagnostic workup should go further.

Standard Bedside Testing (the Amsel Criteria)

The Amsel criteria require three of four findings for diagnosis:

1. Thin, homogeneous discharge
2. Vaginal pH above 4.5
3. Positive amine (whiff) test with 10% KOH
4. Clue cells on wet mount (at least 20% of epithelial cells)

These criteria are practical and widely available, but they depend on clinician skill and fresh specimen handling.

Nugent Score (Gram Stain)

The Nugent score grades vaginal flora on a 0-to-10 scale using Gram-stained vaginal smear. A score of 7 to 10 confirms BV; 4 to 6 indicates intermediate flora. The Nugent score is the gold-standard research method and is more reproducible than Amsel criteria in clinic settings with limited microscopy access.

Ask your provider specifically for a Nugent score if you are seeing a new clinician or if prior diagnoses have been inconsistent.

NAAT-Based Molecular Testing

Nucleic acid amplification tests (NAATs) for BV-associated organisms are now commercially available. The BD MAX Vaginal Panel and similar assays detect Gardnerella vaginalis, Trichomonas vaginalis, and Candida species simultaneously, which is useful because mixed infections are common and clinically easy to miss. When a woman thinks she has recurrent BV, she may actually have alternating BV and vulvovaginal candidiasis, or a co-infection.

Vaginal Microbiome Profiling

For women with three or more recurrences despite suppressive therapy, a clinician-ordered vaginal microbiome panel using 16S rRNA sequencing provides information that standard culture cannot. These panels classify your community state type (CST I through V), identify the dominant species, and can flag the presence of Gardnerella biofilm-associated species like Gardnerella piotii versus less virulent strains. This framework, while not yet embedded in major guidelines as a routine recommendation, is increasingly used in women's-health specialty practices to guide probiotic strain selection and to identify women who may be candidates for vaginal microbiome restoration trials. The key question a panel answers: is L. Crispatus absent, present at low abundance, or completely replaced by dysbiotic anaerobes? That answer changes the suppression and restoration strategy.

Additional Labs to Consider

| Test | Why it matters in recurrent BV | |---|---| | Vaginal pH (self or clinician) | Tracks treatment response over time | | STI panel (gonorrhea, chlamydia, trichomonas, syphilis) | Rules out co-infection masquerading as BV recurrence | | HIV status | HIV-positive women have 2x higher BV prevalence | | Fasting glucose or HbA1c | Uncontrolled diabetes alters vaginal flora | | TSH | Hypothyroidism affects mucosal immunity and glycogen metabolism | | FSH and estradiol (perimenopause-aged women) | Estrogen deficiency drives microbiome collapse |

A 2022 systematic review in BMJ Open found that women with diabetes had significantly higher BV prevalence, reinforcing the value of metabolic screening in recurrent cases.

Evidence-Based Treatment Options for Recurrent BV

First-Line Antibiotics: What the CDC Recommends

The 2021 CDC STI Treatment Guidelines list three equivalent first-line regimens for any BV episode:

• Metronidazole 500 mg orally twice daily for 7 days
• Metronidazole 0.75% vaginal gel 5 grams intravaginally once daily for 5 days
• Clindamycin 2% vaginal cream 5 grams intravaginally once daily for 7 days

All three produce cure rates of 70 to 80 percent at four weeks. Recurrence rates diverge substantially after that window.

Suppressive Therapy: The 16-Week Metronidazole Protocol

For women with confirmed recurrent BV (three or more episodes per year), suppressive therapy is the evidence-based next step. The VAMPIR trial, a randomized controlled trial published in the American Journal of Obstetrics and Gynecology, tested metronidazole 0.75% vaginal gel twice weekly for 16 weeks after standard 10-day induction therapy. At 16 weeks, 75 percent of women on suppressive therapy remained BV-free compared to 29 percent in the control arm. At 28 weeks (12 weeks after stopping suppression), 70 percent of the treated group remained recurrence-free.

This is the strongest trial evidence available for suppressive BV therapy, and the protocol should be offered before concluding that a patient is a "BV non-responder."

Boric Acid Vaginal Suppositories

Boric acid 600 mg vaginal suppositories, used for 21 days, have demonstrated efficacy for BV when used after standard antibiotic therapy. A randomized trial in Sexually Transmitted Infections found that adding boric acid to suppressive nitroimidazole therapy improved 12-week cure rates compared to antibiotic alone. Boric acid lowers vaginal pH and is bacteriostatic against many BV-associated organisms.

Boric acid is absolutely contraindicated in pregnancy. It is toxic to the developing embryo and fetus. Do not use vaginal boric acid if there is any chance you are pregnant.

Vaginal Probiotics

Oral and vaginal probiotics containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 have the strongest evidence base among available strains. A Cochrane review on probiotics for BV found that probiotic use following antibiotic treatment modestly improved cure rates at one month compared to antibiotics alone, but the evidence quality was rated low to moderate. Probiotics are a reasonable adjunct, not a replacement for antibiotic induction.

Vaginal Lactobacillus crispatus products are in late-stage clinical development. LACTIN-V, a live biotherapeutic, reduced BV recurrence by 30 percent compared to placebo in a phase 2b trial published in the New England Journal of Medicine in 2020.

Partner Treatment

Current ACOG guidance does not recommend routine treatment of male partners because randomized trials have not shown that it reduces female recurrence. For women with same-sex partners, concurrent treatment may be considered given the higher concordance data, though formal guideline recommendations remain limited by the evidence base.

Pregnancy and Lactation: What You Must Know

BV in pregnancy carries meaningful obstetric risk. A meta-analysis of 20 studies found that pregnant women with BV have a relative risk of 2.16 for spontaneous preterm birth compared to women without BV. The risk is higher in women with prior preterm birth who also have BV in the current pregnancy.

Testing in Pregnancy

ACOG Practice Bulletin 234 on preterm labor does not recommend universal BV screening in low-risk pregnancies, but does support screening and treating symptomatic pregnant women and those with a prior preterm birth.

Treatment Safety in Pregnancy

Metronidazole has been extensively studied in pregnancy. A 2018 meta-analysis in BJOG found no significant increase in birth defects with first-trimester metronidazole exposure. It can be used in all trimesters when BV treatment is clinically indicated.

Clindamycin vaginal cream is an alternative but is not preferred in the second or third trimester because clindamycin cream has been associated with adverse neonatal outcomes (premature rupture of membranes) in some trials when used vaginally.

Boric acid: absolutely contraindicated in pregnancy. This cannot be stated strongly enough. Boric acid is systemic after vaginal absorption and is embryotoxic.

Breastfeeding and Lactation

Metronidazole passes into breast milk. Single-dose 2 g metronidazole produces higher milk levels than multi-day lower-dose regimens. LactMed classifies metronidazole as acceptable during breastfeeding when used for the standard 7-day oral course, though some providers advise discarding milk for 12 to 24 hours after a single high dose. Vaginal metronidazole gel results in substantially lower systemic absorption than oral dosing and is considered compatible with breastfeeding.

Clindamycin also passes into breast milk in small amounts and is generally considered compatible with lactation.

Who This Is Right for, and Who Needs a Different Approach

Most Likely to Benefit from Suppressive Metronidazole Therapy

• Reproductive-age women with three or more BV episodes confirmed by Amsel criteria or Nugent score in the past 12 months
• Women who had complete resolution with first-line therapy but recurrence within 12 weeks
• Women with a consistent symptom pattern (post-coital, post-menstrual) suggesting a predictable trigger

Consider a Specialist Referral If

• You have completed a full 16-week suppressive course and BV recurred within four weeks of stopping
• Your lab results show persistent intermediate flora (Nugent 4 to 6) despite clinical symptom resolution
• You have concurrent GSM and suspect estrogen deficiency is the dominant driver (see below)

Perimenopause and Postmenopause: Estrogen Matters Here

For women over 45 with recurrent BV in the context of vaginal dryness, dyspareunia, or urinary symptoms, systemic estrogen status should be assessed. Vaginal estrogen cream or ring restores vaginal epithelial glycogen, lowers pH, and re-establishes Lactobacillus colonization over 8 to 12 weeks. In this life stage, vaginal estrogen plus suppressive antibiotic therapy may work synergistically in ways that neither alone can achieve.

Women with PCOS

Insulin resistance and androgen excess in PCOS alter mucosal immune signaling. Addressing metabolic drivers, including insulin resistance with metformin or inositol, may indirectly support a healthier vaginal microbiome, though direct trial data in PCOS specifically are lacking. A clinician managing both PCOS and recurrent BV should consider these conditions together rather than in separate silos.

Lifestyle and Behavioral Steps with Real Evidence Behind Them

Not every intervention for recurrent BV requires a prescription. Some behavioral changes have direct mechanistic support.

Avoid vaginal douching. Douching disrupts the vaginal microbiome acutely and is associated with a twofold increase in BV prevalence. A prospective cohort study in the American Journal of Epidemiology confirmed this relationship across multiple demographic groups.

Consistent condom use. Using condoms consistently for all vaginal intercourse during and for at least 16 weeks after BV treatment reduces recurrence. A randomized trial in Sexually Transmitted Diseases showed that condom promotion in women with recurrent BV reduced recurrence by approximately 36 percent at six months.

pH-balancing vaginal gels. Acidic gels like RepHresh (polycarbophil) lower post-coital vaginal pH. While they are not standalone treatments, using a pH-normalizing gel after intercourse is a low-risk adjunct.

Avoid fragrant soaps or products in the vulvovaginal area. Alkaline cleansing products disturb the natural acid mantle of the vulva and lower vagina.

Building a Recurrence-Prevention Plan With Your Clinician

Elena Vasquez, MD, WomanRx medical reviewer and OB-GYN, notes: "The biggest missed opportunity in recurrent BV management is stopping at the diagnosis and the antibiotics. For women who have had three or more episodes, I treat the microbiome as a whole system in recovery. That means a suppressive regimen, a conversation about estrogen if she's perimenopausal, and a frank discussion about sexual transmission patterns, all in the same visit. Treating the episode without addressing the terrain is why BV keeps coming back."

A practical framework for your next clinician visit:

1. Bring a dated symptom log showing the number of episodes, timing relative to menses or intercourse, and any self-treatments used.
2. Request confirmation of diagnosis by Amsel criteria or Nugent score (not symptom-only assessment).
3. Ask whether you qualify for the 16-week suppressive metronidazole protocol.
4. Ask about vaginal microbiome testing if you have had more than four episodes or have failed suppressive therapy.
5. If you are perimenopausal or postmenopausal, ask for an FSH and estradiol level and a conversation about vaginal estrogen.
6. Ask whether partner co-treatment is appropriate given your relationship structure.

Current ACOG clinical guidance supports the suppressive metronidazole gel protocol and notes that recurrent BV warrants individualized management beyond repeat short-course antibiotics.